Ascletis Selects for Clinical Development a Fixed-Dose Combination of First-in-Class Oral Small Molecule GIPR Agonist, ASC48, and Oral Small Molecule GLP-1R Agonist, ASC30
– ASC48 is a potentially first-in-class oral small molecule GIPR agonist. – ASC48 demonstrated an EC50 of 1 p…















